{
  "query": "BMY",
  "resolved": {
    "ticker": "BMY",
    "cik": "0000014272",
    "title": "BRISTOL MYERS SQUIBB CO"
  },
  "signals": [
    {
      "type": "trial_to_filing",
      "headline": "BRISTOL MYERS SQUIBB CO (BMY) — PHASE2 primary completion in ~44 days",
      "entity": "Bristol-Myers Squibb",
      "ticker": "BMY",
      "cik": "0000014272",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE2)",
        "detail": "Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease",
        "nctId": "NCT06268886",
        "date": "2026-12-17"
      },
      "observed": {
        "event": "primary completion in ~44 days",
        "nctId": "NCT06268886"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 3 initiation",
        "leadTime": "18-36 mo",
        "baseRate": 0.29,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 28% (Wong/Siah/Lo 2019)",
      "confidence": 0.55,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT06268886",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "BRISTOL MYERS SQUIBB CO (BMY) — PHASE2 protocol updated 1 days ago",
      "entity": "Bristol-Myers Squibb",
      "ticker": "BMY",
      "cik": "0000014272",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE2)",
        "detail": "A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)",
        "nctId": "NCT07492680",
        "date": "2028-08-15"
      },
      "observed": {
        "event": "protocol updated 1 days ago",
        "nctId": "NCT07492680"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 3 initiation",
        "leadTime": "18-36 mo",
        "baseRate": 0.29,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 28% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07492680",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "BRISTOL MYERS SQUIBB CO (BMY) — PHASE3 protocol updated 7 days ago",
      "entity": "Bristol-Myers Squibb",
      "ticker": "BMY",
      "cik": "0000014272",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease",
        "nctId": "NCT06976216",
        "date": "2028-09-11"
      },
      "observed": {
        "event": "protocol updated 7 days ago",
        "nctId": "NCT06976216"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT06976216",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272&type=8-K"
      }
    }
  ],
  "recentFilings": {
    "name": "BRISTOL MYERS SQUIBB CO",
    "sicDescription": "Pharmaceutical Preparations",
    "filings": [
      {
        "form": "8-K",
        "date": "2026-10-29",
        "accession": "0000014272-26-000022",
        "items": "2.02,7.01,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-07-30",
        "accession": "0000014272-26-000018",
        "items": "2.02,7.01,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-05-08",
        "accession": "0001140361-26-020036",
        "items": "5.07"
      },
      {
        "form": "8-K",
        "date": "2026-04-30",
        "accession": "0000014272-26-000008",
        "items": "2.02,7.01,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-02-05",
        "accession": "0000014272-26-000002",
        "items": "2.02,7.01,9.01"
      }
    ]
  },
  "disclaimer": "Research/informational. NOT investment advice.",
  "generatedAt": "2026-11-03T09:00:20.748Z"
}